<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">BMC Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">BMC Bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>BMC Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1471-2105</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7987121</article-id>
    <article-id pub-id-type="publisher-id">4076</article-id>
    <article-id pub-id-type="doi">10.1186/s12859-021-04076-w</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Software</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SAveRUNNER: an R-based tool for drug repurposing</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Fiscon</surname>
          <given-names>Giulia</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9393-2047</contrib-id>
        <name>
          <surname>Paci</surname>
          <given-names>Paola</given-names>
        </name>
        <address>
          <email>paci@diag.uniroma1.it</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.5326.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 1940 4177</institution-id><institution>Institute for Systems Analysis and Computer Science, </institution><institution>Antonio Ruberti”, National Research Council, </institution></institution-wrap>Rome, Italy </aff>
      <aff id="Aff2"><label>2</label>Fondazione Per La Medicina Personalizzata, Via Goffredo Mameli, 3/1, Genoa, Italy </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.7841.a</institution-id><institution>Department of Computer, Control and Management Engineering, </institution><institution>Sapienza University of Rome, </institution></institution-wrap>Rome, Italy </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>23</day>
      <month>3</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>23</day>
      <month>3</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2021</year>
    </pub-date>
    <volume>22</volume>
    <elocation-id>150</elocation-id>
    <history>
      <date date-type="received">
        <day>7</day>
        <month>12</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>3</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2021</copyright-statement>
      <license license-type="OpenAccess">
        <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">Currently, no proven effective drugs for the novel coronavirus disease COVID-19 exist and despite widespread vaccination campaigns, we are far short from herd immunity. The number of people who are still vulnerable to the virus is too high to hamper new outbreaks, leading a compelling need to find new therapeutic options devoted to combat SARS-CoV-2 infection. Drug repurposing represents an effective drug discovery strategy from existing drugs that could shorten the time and reduce the cost compared to de novo drug discovery.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par2">We developed a network-based tool for drug repurposing provided as a freely available R-code, called SAveRUNNER (Searching off-lAbel dRUg aNd NEtwoRk), with the aim to offer a promising framework to efficiently detect putative novel indications for currently marketed drugs against diseases of interest. SAveRUNNER predicts drug–disease associations by quantifying the interplay between the drug targets and the disease-associated proteins in the human interactome through the computation of a novel network-based similarity measure, which prioritizes associations between drugs and diseases located in the same network neighborhoods.</p>
      </sec>
      <sec>
        <title>Conclusions</title>
        <p id="Par3">The algorithm was successfully applied to predict off-label drugs to be repositioned against the new human coronavirus (2019-nCoV/SARS-CoV-2), and it achieved a high accuracy in the identification of well-known drug indications, thus revealing itself as a powerful tool to rapidly detect potential novel medical indications for various drugs that are worth of further investigation. SAveRUNNER source code is freely available at <ext-link ext-link-type="uri" xlink:href="https://github.com/giuliafiscon/SAveRUNNER.git">https://github.com/giuliafiscon/SAveRUNNER.git</ext-link>, along with a comprehensive user guide.</p>
      </sec>
      <sec>
        <title>Supplementary Information</title>
        <p>The online version contains supplementary material available at 10.1186/s12859-021-04076-w.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Drug repurposing</kwd>
      <kwd>Network theory</kwd>
      <kwd>Network medicine</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>PRIN 2017 - Settore ERC LS2</institution>
        </funding-source>
        <award-id>20178L3P38</award-id>
        <principal-award-recipient>
          <name>
            <surname>Paci</surname>
            <given-names>Paola</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2021</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p id="Par10">Currently, we are still facing a global pandemic caused by the new coronavirus SARS-CoV-2. The viral waves in Europe and the United States restarted in August and mid-September are driving the steep upward trend of the global daily tally for new COVID-19 cases that increases up to new high records, suggesting that this wave will be worse than the one that swept the countries over the spring–summer.</p>
    <p id="Par11">Even though mass vaccination campaigns have been started across countries, it remains difficult to achieve herd immunity in a short time and the proportion of the population that is susceptible to the new coronavirus is still insufficient for new outbreaks to peter out. To meet the compelling need of finding new therapeutic options devoted to combat SARS-CoV-2 infection [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], promising insights come from drug repurposing, a recent strategy for identifying novel uses for drugs approved by the US Food and Drug Administration (FDA) outside the scope of their original medical indication [<xref ref-type="bibr" rid="CR3">3</xref>]. Establishing whether an ‘old drug’ can be reused for new therapeutic purposes represents a faster and cheaper alternative to de novo drug discovery, which generally takes 2–3 billion dollars and 12–15 years [<xref ref-type="bibr" rid="CR3">3</xref>]. Hence, drug repurposing strategy appears as a powerful solution for emerging diseases, such as COVID-19 [<xref ref-type="bibr" rid="CR4">4</xref>]. In this context, we developed SAveRUNNER (Searching off-lAbel dRUg aNd NEtwoRk), a new network-based tool for drug repurposing that exploits concepts from the emerging field of network medicine [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR9">9</xref>]. According to the new paradigm of Network Medicine, diseases can be interpreted as local perturbations in the human interactome map (i.e., the cellular network of all physical molecular interactions), where the molecular determinants of a given disease (<italic>disease genes</italic>) are not randomly scattered, but co-localize and agglomerate in specific regions (<italic>disease modules</italic>) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Perturbations in these disease modules can contribute to pathobiological phenotype manifestation. From this perspective, also the drugs action can be interpreted as a local perturbation of the interactome and thus, for a drug to be on-target effective against a specific disease or to cause off-target adverse effects, its target proteins should be within or in the immediate vicinity of the corresponding disease module [<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR13">13</xref>]. Inspired by this philosophy, SAveRUNNER predicts drug–disease associations by quantifying the vicinity between the drug targets and the disease-associated proteins in the human interactome via a novel network-based similarity measure that rewards associations between drugs and diseases located in the same network neighborhoods. SAveRUNNER yielded a high accuracy in the identification of well-known drug indications, as well as being able to provide interesting clues regarding off-label prediction of drugs to be repositioned against the new human coronavirus [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
  </sec>
  <sec id="Sec2">
    <title>Implementation</title>
    <p id="Par12">SAveRUNNER (Searching off-lAbel dRUg aNd NEtwoRk) is a network-based algorithm for drug repurposing that, taking as input a list of drug targets and disease genes, predicts drug-disease associations by computing a new network-based similarity measure to prioritize associations between drugs and diseases located in the same network neighborhoods by performing the following steps (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>SAveRUNNER conceptual organization. SAveRUNNER takes as input a list of drug-target interactions and disease-gene associations, and releases as output predicted drug-disease associations by performing seven steps (dashed box of this flowchart). In particular, Steps 1–3 bring to the construction of a proximity-based bipartite drug-disease network, where nodes are both drugs and diseases, edges are the statistically significant drug-disease associations (<italic>p </italic>value <inline-formula id="IEq18"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\le 0.05$$\end{document}</tex-math><mml:math id="M2"><mml:mrow><mml:mo>≤</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq18.gif"/></alternatives></inline-formula>, or z-score <inline-formula id="IEq19"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\le -1.65$$\end{document}</tex-math><mml:math id="M4"><mml:mrow><mml:mo>≤</mml:mo><mml:mo>-</mml:mo><mml:mn>1.65</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq19.gif"/></alternatives></inline-formula>), weighted according to the proximity values; Steps 4–7 bring to the construction of a similarity-based bipartite drug-disease network, where the weights represent the adjusted similarity measure computed to prioritize the predicted drug-disease associations by rewarding the associations between drugs and diseases belonging to the same network neighborhood. Finally, the drug-disease associations predicted by SAveRUNNER were evaluated by performing a ROC curve probability analysis (solid line box of this flowchart). The ROC curve is computed for SAveRUNNER algorithm by plotting the true positive rate (TPR) placed on Y-axis against the false positive rate (FPR) placed on X-axis at various threshold settings. Diagonal grey line represents the line of no-discrimination between positive class (known drug-disease associations) and negative class (unknown drug-disease associations)</p></caption><graphic xlink:href="12859_2021_4076_Fig1_HTML" id="MO1"/></fig></p>
    <sec id="Sec3">
      <title>Computation of network proximity</title>
      <p id="Par13">SAveRUNNER implements the network-based proximity measure (Eq. <xref rid="Equ1" ref-type="">1</xref>) to investigate the extent to which disease and drug modules are close in the human interactome [<xref ref-type="bibr" rid="CR11">11</xref>]:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p\left(T,S\right)=\frac{1}{\Vert T\Vert }\sum_{t\epsilon T}\underset{s\epsilon S}{\mathit{min}}d(t,s)$$\end{document}</tex-math><mml:math id="M6" display="block"><mml:mrow><mml:mi>p</mml:mi><mml:mfenced close=")" open="("><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mi>S</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mo stretchy="false">‖</mml:mo><mml:mi>T</mml:mi><mml:mo stretchy="false">‖</mml:mo></mml:mrow></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mi>ϵ</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:munder><mml:munder><mml:mi mathvariant="italic">min</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>ϵ</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:munder><mml:mi>d</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xlink:href="12859_2021_4076_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>which is the average shortest path length between drug targets <inline-formula id="IEq1"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t$$\end{document}</tex-math><mml:math id="M8"><mml:mi>t</mml:mi></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq1.gif"/></alternatives></inline-formula> in the drug module <inline-formula id="IEq2"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$T$$\end{document}</tex-math><mml:math id="M10"><mml:mi>T</mml:mi></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq2.gif"/></alternatives></inline-formula> and the nearest disease genes <inline-formula id="IEq3"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$s$$\end{document}</tex-math><mml:math id="M12"><mml:mi>s</mml:mi></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq3.gif"/></alternatives></inline-formula> in the disease module <inline-formula id="IEq4"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$S$$\end{document}</tex-math><mml:math id="M14"><mml:mi>S</mml:mi></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq4.gif"/></alternatives></inline-formula>.</p>
    </sec>
    <sec id="Sec4">
      <title>Computation of z-score proximity and <italic>p</italic> values</title>
      <p id="Par14">The proximity value between a drug module T and a disease module S was z-score normalized by applying a degree-preserving randomization procedure. In particular, to compute the z-scores and the corresponding <italic>p </italic>values, SAveRUNNER builds a reference distance distribution corresponding to the expected distance between two randomly selected groups of proteins with the same size and degree distribution of the original sets of disease proteins and drug targets in the human interactome. This procedure is repeated 1,000 times and the z statistic, together with its <italic>p </italic>value, is computed by using the mean and the standard deviation of the reference distance distribution. A <italic>p </italic>value <inline-formula id="IEq5"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\le$$\end{document}</tex-math><mml:math id="M16"><mml:mo>≤</mml:mo></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq5.gif"/></alternatives></inline-formula> 0.05 (corresponding to a z <inline-formula id="IEq6"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\le$$\end{document}</tex-math><mml:math id="M18"><mml:mo>≤</mml:mo></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq6.gif"/></alternatives></inline-formula>-1.65) was expected for a drug and disease module more proximal than expected by chance.</p>
    </sec>
    <sec id="Sec5">
      <title>Selection of statistically significant drug-disease associations</title>
      <p id="Par15">In order to filter out statistically insignificant drug-disease associations, a significance level for the <italic>p </italic>values should be set (typically, <italic>p </italic>value <inline-formula id="IEq7"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\le$$\end{document}</tex-math><mml:math id="M20"><mml:mo>≤</mml:mo></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq7.gif"/></alternatives></inline-formula> 0.05). It means that, given a disease <italic>A</italic> and a drug <italic>b</italic>, if the <italic>p </italic>value associated to their distance in the human interactome is smaller of the chosen significance level, the probability that the off-label drug <italic>b</italic> would be effective for this disease <italic>A</italic> is greater than expected by chance.</p>
    </sec>
    <sec id="Sec6">
      <title>Computation of network similarity</title>
      <p id="Par16">The network proximity measure <italic>p</italic> defined in Eq. 1 is translated in a similarity measure (Eq. <xref rid="Equ2" ref-type="">2</xref>) assuming values in the range [0–1]:<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$similarity= \frac{\mathrm{max}\left(p\right)-p}{\mathrm{max}(p)}$$\end{document}</tex-math><mml:math id="M22" display="block"><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">max</mml:mi><mml:mfenced close=")" open="("><mml:mi>p</mml:mi></mml:mfenced><mml:mo>-</mml:mo><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">max</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="12859_2021_4076_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par17">Null similarity means that the corresponding disease and drug modules are very distal in the human interactome (i.e., <inline-formula id="IEq8"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p$$\end{document}</tex-math><mml:math id="M24"><mml:mi>p</mml:mi></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq8.gif"/></alternatives></inline-formula> is maximum); whereas maximum similarity means that the corresponding disease and drug modules are very proximal in the human interactome (i.e., <inline-formula id="IEq9"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p$$\end{document}</tex-math><mml:math id="M26"><mml:mi>p</mml:mi></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq9.gif"/></alternatives></inline-formula> equal to zero).</p>
    </sec>
    <sec id="Sec7">
      <title>Cluster detection</title>
      <p id="Par18">SAveRUNNER exploits a clustering algorithm based on greedy optimization of the network modularity [<xref ref-type="bibr" rid="CR15">15</xref>] to detect groups of drugs and diseases in such a way that members in the same group (cluster) are more similar to each other than to those in other groups (clusters). The quality of each cluster is evaluated by SAveRUNNER through the computation of the quality cluster (<inline-formula id="IEq10"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$QC)$$\end{document}</tex-math><mml:math id="M28"><mml:mrow><mml:mi>Q</mml:mi><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq10.gif"/></alternatives></inline-formula> score (Eq. <xref rid="Equ3" ref-type="">3</xref>):<disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$QC=\frac{{W}_{in}}{{W}_{in}+ {W}_{out}+P}$$\end{document}</tex-math><mml:math id="M30" display="block"><mml:mrow><mml:mi>Q</mml:mi><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi mathvariant="italic">in</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi mathvariant="italic">in</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi mathvariant="italic">out</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>P</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="12859_2021_4076_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq11"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${W}_{in}$$\end{document}</tex-math><mml:math id="M32"><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi mathvariant="italic">in</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq11.gif"/></alternatives></inline-formula> denotes the total weight of edges within the cluster, <inline-formula id="IEq12"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${W}_{out}$$\end{document}</tex-math><mml:math id="M34"><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi mathvariant="italic">out</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq12.gif"/></alternatives></inline-formula> denotes the total weight of edges connecting this cluster to the rest of network, and <inline-formula id="IEq13"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P$$\end{document}</tex-math><mml:math id="M36"><mml:mi>P</mml:mi></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq13.gif"/></alternatives></inline-formula> is a penalty term which considers the node density within the cluster (i.e., the ratio of network nodes within each cluster).</p>
    </sec>
    <sec id="Sec8">
      <title>Adjustment of network similarity</title>
      <p id="Par19">SAveRUNNER uses the <italic>QC</italic> score to reward associations between drugs and diseases belonging to the same cluster, based on the assumption that if a drug and a disease group together is more likely that the drug can be effectively repurposed for that disease. Thus, drug and the disease that are members of the same cluster tend to be “more similar” and this translates into the adjustment for the similarity (Eq. <xref rid="Equ4" ref-type="">4</xref>):<disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$similarity=(1+QC)\bullet similarity$$\end{document}</tex-math><mml:math id="M38" display="block"><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>Q</mml:mi><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>∙</mml:mo><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:math><graphic xlink:href="12859_2021_4076_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par20">In this way, if two nodes fall in the same cluster their similarity value increases by a factor proportional to the <inline-formula id="IEq14"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$QC$$\end{document}</tex-math><mml:math id="M40"><mml:mrow><mml:mi mathvariant="italic">QC</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq14.gif"/></alternatives></inline-formula> score of the cluster which they belong; otherwise whether two nodes do not fall in the same cluster <inline-formula id="IEq15"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$QC$$\end{document}</tex-math><mml:math id="M42"><mml:mrow><mml:mi mathvariant="italic">QC</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq15.gif"/></alternatives></inline-formula> is set to zero and their similarity value does not change.</p>
    </sec>
    <sec id="Sec9">
      <title>Normalization of network similarity</title>
      <p id="Par21">The similarity measure defined in Eq. 4 was normalized by applying the following sigmoid function (Eq. <xref rid="Equ5" ref-type="">5</xref>):<disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f(x)= \frac{1}{1+{e}^{-c(x-d)}}$$\end{document}</tex-math><mml:math id="M44" display="block"><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>-</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="12859_2021_4076_Article_Equ5.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq16"><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$x$$\end{document}</tex-math><mml:math id="M46"><mml:mi>x</mml:mi></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq16.gif"/></alternatives></inline-formula> is the adjusted similarity measure (Eq. <xref rid="Equ4" ref-type="">4</xref>), <italic>d</italic> is the sigmoid midpoint (i.e., the value at which the function approaches to 0.5), <italic>c</italic> is the sigmoid steepness.</p>
      <p id="Par22">Eventually, SAveRUNNER releases a list of predicted/prioritized associations between drugs and diseases as a weighted bipartite drug-disease network, in which one set of nodes corresponds to drugs and the other one corresponds to diseases. A link between a drug and a disease occurs if the corresponding drug targets and disease genes are nearby in the interactome more than expected by chance (<italic>p </italic>value <inline-formula id="IEq17"><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\le$$\end{document}</tex-math><mml:math id="M48"><mml:mo>≤</mml:mo></mml:math><inline-graphic xlink:href="12859_2021_4076_Article_IEq17.gif"/></alternatives></inline-formula> 0.05) and the weight of their interaction corresponds to the adjusted and normalized similarity value.</p>
    </sec>
  </sec>
  <sec id="Sec10">
    <title>Results</title>
    <sec id="Sec11">
      <title>SAveRUNNER predictions of repurposable drugs in relation to COVID-19</title>
      <p id="Par23">In order to evaluate the effectiveness of predicted drug–disease associations, we applied SAveRUNNER on several human diseases for which original medical indications were available. In particular, given the deep impact of the ongoing COVID-19 pandemic, we selected a panel of 15 disorders, including COVID-19 and 14 diseases related to COVID-19 (SARS-CoV-2) for genetic similarity, comorbidity, or for their association to drugs with ongoing clinical trials for treating COVID-19 patients. We tested Severe Acute Respiratory Syndrome (SARS) since it is caused by the coronavirus with the highest sequence identity with SARS-CoV-2 [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR16">16</xref>] and there exists a well-established knowledge of its associated disease genes [<xref ref-type="bibr" rid="CR17">17</xref>]. Moreover, we included also diabetes, cardiovascular diseases, and hypertension, whose comorbidity in COVID-19 patients is well documented [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]; and finally other viral infections (i.e., malaria, HIV and Ebola) and immune disorders (i.e., rheumatoid arthritis), since drugs approved for their treatment are being investigated for their potential effect to fight coronavirus disease [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR27">27</xref>]. COVID-19-associated genes were download from [<xref ref-type="bibr" rid="CR28">28</xref>], where the authors identified 332 human proteins interacting with 26 SARS-CoV-2 proteins by using affinity purification mass spectrometry. Although this study has been carried out on human HEK293T kidney cells that do not represent the primary physiological site of infection, the authors verified that these proteins were preferentially highly expressed in lung tissue (the typical environment where the virus causes a major damage). Yet, the disease-associated genes for the other selected 14 diseases were downloaded from Phenopedia [<xref ref-type="bibr" rid="CR17">17</xref>], the drug-target interactions were acquired from DrugBank [<xref ref-type="bibr" rid="CR29">29</xref>], and the human interactome was retrieved from [<xref ref-type="bibr" rid="CR11">11</xref>] (Fig. <xref rid="Fig2" ref-type="fig">2</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Used data resources. Summary of the all input data collection with the corresponding links to retrieve them</p></caption><graphic xlink:href="12859_2021_4076_Fig2_HTML" id="MO2"/></fig></p>
      <p id="Par24">The list of network-predicted drugs potentially able to treat SARS-CoV-2 infection contains a total of 98 drugs (Additional file <xref rid="MOESM2" ref-type="media">2</xref>), including 54 (i.e., 55%) COVID-19 specific and 44 (i.e., 45%) in common with the candidate repurposable drugs found for SARS-CoV. The results of this study are broadly discussed in an our recent publication [<xref ref-type="bibr" rid="CR14">14</xref>]. In Additional file <xref rid="MOESM3" ref-type="media">3</xref>, the data analysis details step-by-step were reported via a working example of SAveRUNNER application to COVID-19, from data collection, network, association analysis and predicted repurposable drugs.</p>
    </sec>
    <sec id="Sec12">
      <title>SAveRUNNER performance evaluation</title>
      <p id="Par25">The drug–disease associations predicted by the SAveRUNNER was then evaluated in terms of the Receiver Operating Characteristic (ROC) probability curve analysis (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The predicted associations were ranked according to increasing <italic>p </italic>values and a “real association” was assigned according to the well-known drug-disease associations downloaded from Therapeutic Target Database (TTD) [<xref ref-type="bibr" rid="CR30">30</xref>]: 1 corresponds to predicted drug-disease association that is already known, 0 otherwise. For a specified <italic>p </italic>value threshold, the true positive rate (i.e., sensitivity) was calculated as the fraction of known associations that are correctly predicted, while the false positive rate (i.e., 1-specificity) was computed as the fraction of unknown associations that are predicted. The ROC probability curve was drawn based on these measures at different thresholds and the corresponding Area Under the Curve (AUC) was computed. The higher the AUC, the better the algorithm is at distinguishing between two classes (i.e., known drug-disease associations vs. unknown drug-disease associations). SAveRUNNER achieved over 70% accuracy (AUC = 0.73) for identifying well-known drug-disease relationships (Fig. <xref rid="Fig1" ref-type="fig">1</xref>), meaning that there is 73% chance that the SAveRUNNER algorithm will be able to distinguish between positive class (known drug-disease associations) and negative class (unknown drug-disease associations).</p>
    </sec>
    <sec id="Sec13">
      <title>Comparison with other methods</title>
      <p id="Par26">Among network-based methods proposed to predict direct drug–disease associations for drug repositioning [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR31">31</xref>–<xref ref-type="bibr" rid="CR35">35</xref>], the MBiRW algorithm has been shown to outperform other well-known network-based prediction methods [<xref ref-type="bibr" rid="CR36">36</xref>–<xref ref-type="bibr" rid="CR38">38</xref>] in correctly predicting true drug–disease associations. MBiRW adopts an effective mechanism to measure similarity for drugs and diseases and applies a Bi-Random walk (BiRW) algorithm to predict potential new indications for existing drugs [<xref ref-type="bibr" rid="CR35">35</xref>]. These captivating results prompted us to implement a BiRW-based algorithm against which we compared the performance of SAveRUNNER. Details of BiRW-based algorithm implementation are provided as Additional file <xref rid="MOESM4" ref-type="media">4</xref>.</p>
      <p id="Par27">We evaluated and compared the drug–disease predictions provided by BiRW and SAveRUNNER in terms of ROC probability curves with their corresponding AUC. In particular, we found that SAveRUNNER yielded over 70% accuracy (AUC = 0.73) for identifying well-known drug-disease relationships and overcame the one obtained by the BiRW-based algorithm (AUC = 0.59). In other words, there is 73% chance that SAveRUNNER algorithm will be able to distinguish between known and unknown drug-disease associations against the 59% of the BiRW-based algorithm (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>ROC curves for predicting drug–disease associations. The ROC curve is computed for SAveRUNNER algorithm (light blue curve) and BiRW algorithm (orange curve) by plotting the true positive rate (TPR), i.e., sensitivity placed on Y-axis against the false positive rate (FPR), i.e., 1-specificity placed on X-axis at various threshold settings. Diagonal grey line represents the line of no-discrimination between positive class (known drug-disease associations) and negative class (unknown drug-disease associations)</p></caption><graphic xlink:href="12859_2021_4076_Fig3_HTML" id="MO3"/></fig></p>
      <p id="Par28">To further evaluate the performances of SAveRUNNER, we compared its outcomes with the predictions obtained by a recent study, where the authors integrated several network-based drug repurposing strategies to prioritize 81 promising repurposing candidates against COVID-19 [<xref ref-type="bibr" rid="CR13">13</xref>]. In particular, they combined three predictive approaches: (1) proximity-based methods that allowed to measure the distance between the viral protein targets and both (i) the targets of approved drugs and (ii) the differentially expressed genes induced by each drug; (2) diffusion-based methods to rank drugs based on the network similarity of their targets to COVID-19 protein targets; (3) machine learning methods relying on artificial intelligence network. These pipelines offered altogether twelve ranked lists that were merged using a rank aggregation algorithm in order to obtain a final list of 81 prioritized repurposable drugs. The overlap between these 81 repurposable drugs and the 98 ones predicted by SAveRUNNER is of 5 drugs, i.e. <italic>isoniazid, lopinavir, romidepsin, sulfinpyrazone, tadalafil.</italic></p>
      <p id="Par29">However, although the use of more methodologies can provide more reliable and feasible drug repurposable candidates, the lack of a unified pipeline makes it difficult for non-expert users to exploit this approach for own research purposes.</p>
    </sec>
  </sec>
  <sec id="Sec110">
    <title>Availability and requirements</title>
    <p id="Par30">
      <list list-type="bullet">
        <list-item>
          <p id="Par31"><italic>Project name</italic>: SAveRUNNER.</p>
        </list-item>
        <list-item>
          <p id="Par32"><italic>Project page</italic>: <ext-link ext-link-type="uri" xlink:href="https://github.com/giuliafiscon/SAveRUNNER.git">https://github.com/giuliafiscon/SAveRUNNER.git</ext-link>.</p>
        </list-item>
        <list-item>
          <p id="Par33"><italic>Operating system(s)</italic>: macOS High Sierra 10.13.6, Windows 10 Pro.</p>
        </list-item>
        <list-item>
          <p id="Par34"><italic>Programming language</italic>: R.</p>
        </list-item>
        <list-item>
          <p id="Par35"><italic>Other requirements</italic>: R version 3.5.1 or higher.</p>
        </list-item>
        <list-item>
          <p id="Par36"><italic>License</italic>: GNU AFFERO GENERAL PUBLIC LICENSE.</p>
        </list-item>
      </list>
    </p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Information</title>
    <sec id="Sec15">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="12859_2021_4076_MOESM1_ESM.xlsx">
            <caption>
              <p><bold>Additional file 1.</bold> Table composed of three separate sheets. The first sheet reports the analyzed diseases with the corresponding number of disease-causing genes. The second sheet reports the analyzed FDA-approved drugs with the corresponding number of target proteins. The third sheet reports the analyzed diseases with the corresponding number of repurposable drugs predicted by SAveRUNNER.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="12859_2021_4076_MOESM2_ESM.xlsx">
            <caption>
              <p><bold>Additional file 2.</bold> List of repurposable drugs for COVID-19 predicted by SAveRUNNER along with their statistics.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM3">
          <media xlink:href="12859_2021_4076_MOESM3_ESM.pdf">
            <caption>
              <p><bold>Additional file 3.</bold> Working example of SAveRUNNER application to COVID-19.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM4">
          <media xlink:href="12859_2021_4076_MOESM4_ESM.pdf">
            <caption>
              <p><bold>Additional file 4.</bold> Implementation of BiRW-based algorithm for drug repurposing.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <glossary>
    <title>Abbreviations</title>
    <def-list>
      <def-item>
        <term>FDA</term>
        <def>
          <p id="Par4">Food and drug administration</p>
        </def>
      </def-item>
      <def-item>
        <term>SAveRUNNER</term>
        <def>
          <p id="Par5">Searching off-lAbel dRUg aNd NEtwoRk</p>
        </def>
      </def-item>
      <def-item>
        <term>QC</term>
        <def>
          <p id="Par6">Quality score</p>
        </def>
      </def-item>
      <def-item>
        <term>AUC</term>
        <def>
          <p id="Par7">Area under the curve</p>
        </def>
      </def-item>
      <def-item>
        <term>TTD</term>
        <def>
          <p id="Par8">Therapeutic target database</p>
        </def>
      </def-item>
      <def-item>
        <term>ROC</term>
        <def>
          <p id="Par9">Receiver operating characteristic</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher's Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>Not applicable.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authors' contributions</title>
    <p>PP conceived and designed the research. PP and GF developed the algorithm and wrote the manuscript. All authors have read and approved the manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This work was financially supported by PRIN 2017—Settore ERC LS2—Codice Progetto 20178L3P38. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>All data generated or analyzed during this study are included in this published article. SAveRUNNER code is open-source and it is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/giuliafiscon/SAveRUNNER.git">https://github.com/giuliafiscon/SAveRUNNER.git</ext-link>, together with an exhaustive and well-documented user guide, which includes a detailed description of all R scripts, all input/output files through a working example of SAveRUNNER application on 15 diseases, including COVID-19.</p>
  </notes>
  <notes>
    <title>Declarations</title>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par37">Not applicable.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication</title>
      <p id="Par38">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par39">The authors declare that they have no competing interests.</p>
    </notes>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cao</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A trial of Lopinavir-Ritonavir in adults hospitalized with severe covid-19</article-title>
        <source>N Engl J Med</source>
        <year>2020</year>
        <volume>382</volume>
        <fpage>1787</fpage>
        <lpage>1799</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id>
        <pub-id pub-id-type="pmid">32187464</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Borba</surname>
            <given-names>MGS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial</article-title>
        <source>JAMA Netw Open</source>
        <year>2020</year>
        <volume>3</volume>
        <fpage>e208857</fpage>
        <lpage>e208857</lpage>
        <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.8857</pub-id>
        <pub-id pub-id-type="pmid">32330277</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pushpakom</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Drug repurposing: progress, challenges and recommendations</article-title>
        <source>Nat Rev Drug Discov</source>
        <year>2019</year>
        <volume>18</volume>
        <fpage>41</fpage>
        <lpage>58</lpage>
        <pub-id pub-id-type="doi">10.1038/nrd.2018.168</pub-id>
        <pub-id pub-id-type="pmid">30310233</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nussinov</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>Artificial intelligence in COVID-19 drug repurposing</article-title>
        <source>Lancet Digit. Health</source>
        <year>2020</year>
        <volume>2</volume>
        <fpage>e667</fpage>
        <lpage>676</lpage>
        <pub-id pub-id-type="doi">10.1016/S2589-7500(20)30192-8</pub-id>
        <pub-id pub-id-type="pmid">32984792</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sonawane</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Weiss</surname>
            <given-names>ST</given-names>
          </name>
          <name>
            <surname>Glass</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sharma</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Network medicine in the age of biomedical big data</article-title>
        <source>Front Genet</source>
        <year>2019</year>
        <volume>10</volume>
        <fpage>294</fpage>
        <pub-id pub-id-type="doi">10.3389/fgene.2019.00294</pub-id>
        <pub-id pub-id-type="pmid">31031797</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Barabási</surname>
            <given-names>A-L</given-names>
          </name>
          <name>
            <surname>Gulbahce</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Loscalzo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Network medicine: a network-based approach to human disease</article-title>
        <source>Nat Rev Genet</source>
        <year>2011</year>
        <volume>12</volume>
        <fpage>56</fpage>
        <lpage>68</lpage>
        <pub-id pub-id-type="doi">10.1038/nrg2918</pub-id>
        <pub-id pub-id-type="pmid">21164525</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Silverman</surname>
            <given-names>EK</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular networks in network medicine: development and applications</article-title>
        <source>WIREs Syst Biol Med</source>
        <year>2020</year>
        <volume>12</volume>
        <fpage>e1489</fpage>
        <pub-id pub-id-type="doi">10.1002/wsbm.1489</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Paci</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene co-expression in the interactome: moving from correlation toward causation via an integrated approach to disease module discovery</article-title>
        <source>Npj Syst Biol Appl</source>
        <year>2021</year>
        <volume>7</volume>
        <fpage>1</fpage>
        <lpage>11</lpage>
        <pub-id pub-id-type="doi">10.1038/s41540-020-00168-0</pub-id>
        <pub-id pub-id-type="pmid">33402683</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Conte</surname>
            <given-names>F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A paradigm shift in medicine: a comprehensive review of network-based approaches</article-title>
        <source>Biochim Biophys Acta BBA Gene Regul Mech</source>
        <year>2020</year>
        <volume>1863</volume>
        <fpage>194416</fpage>
        <pub-id pub-id-type="doi">10.1016/j.bbagrm.2019.194416</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Caldera</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Buphamalai</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Müller</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Menche</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Interactome-based approaches to human disease</article-title>
        <source>Curr Opin Syst Biol</source>
        <year>2017</year>
        <volume>3</volume>
        <fpage>88</fpage>
        <lpage>94</lpage>
        <pub-id pub-id-type="doi">10.1016/j.coisb.2017.04.015</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Network-based approach to prediction and population-based validation of in silico drug repurposing</article-title>
        <source>Nat Commun</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>2691</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-018-05116-5</pub-id>
        <pub-id pub-id-type="pmid">30002366</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2</article-title>
        <source>Cell Discov</source>
        <year>2020</year>
        <volume>6</volume>
        <fpage>1</fpage>
        <lpage>18</lpage>
        <?supplied-pmid 31934347?>
        <pub-id pub-id-type="pmid">31934347</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <mixed-citation publication-type="other">Gysi, D. M. <italic>et al.</italic> Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19. <italic>ArXiv200407229 Cs Q-Bio Stat</italic> (2020).</mixed-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fiscon</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Conte</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Farina</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Paci</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>SAveRUNNER: a network-based algorithm for drug repurposing and its application to COVID-19</article-title>
        <source>PLOS Comput Biol</source>
        <year>2021</year>
        <volume>17</volume>
        <fpage>e1008686</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1008686</pub-id>
        <pub-id pub-id-type="pmid">33544720</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Clauset</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Newman</surname>
            <given-names>MEJ</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Finding community structure in very large networks</article-title>
        <source>Phys Rev E</source>
        <year>2004</year>
        <volume>70</volume>
        <fpage>066111</fpage>
        <pub-id pub-id-type="doi">10.1103/PhysRevE.70.066111</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title>
        <source>Lancet</source>
        <year>2020</year>
        <volume>395</volume>
        <fpage>565</fpage>
        <lpage>574</lpage>
        <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id>
        <pub-id pub-id-type="pmid">32007145</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Clyne</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Khoury</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Gwinn</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations</article-title>
        <source>Bioinformatics</source>
        <year>2010</year>
        <volume>26</volume>
        <fpage>145</fpage>
        <lpage>146</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btp618</pub-id>
        <pub-id pub-id-type="pmid">19864262</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title>
        <source>Lancet</source>
        <year>2020</year>
        <volume>395</volume>
        <fpage>507</fpage>
        <lpage>513</lpage>
        <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id>
        <pub-id pub-id-type="pmid">32007143</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title>
        <source>JAMA</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id>
        <?supplied-pmid 33201198?>
        <pub-id pub-id-type="pmid">33201198</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <mixed-citation publication-type="other">COVID-19: Finding the Right Fit. <italic>DrugBank Blog</italic><ext-link ext-link-type="uri" xlink:href="https://blog.drugbankplus.com/data-driven-approaches-to-identify-potential-covid-19-therapies/">https://blog.drugbankplus.com/data-driven-approaches-to-identify-potential-covid-19-therapies/</ext-link> (2020).</mixed-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title>
        <source>Cell Discov</source>
        <year>2020</year>
        <volume>6</volume>
        <fpage>1</fpage>
        <lpage>4</lpage>
        <pub-id pub-id-type="doi">10.1038/s41421-019-0132-8</pub-id>
        <pub-id pub-id-type="pmid">31934347</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Tian</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</article-title>
        <source>Biosci Trends</source>
        <year>2020</year>
        <volume>14</volume>
        <fpage>72</fpage>
        <lpage>73</lpage>
        <pub-id pub-id-type="doi">10.5582/bst.2020.01047</pub-id>
        <pub-id pub-id-type="pmid">32074550</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Colson</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Rolain</surname>
            <given-names>J-M</given-names>
          </name>
          <name>
            <surname>Lagier</surname>
            <given-names>J-C</given-names>
          </name>
          <name>
            <surname>Brouqui</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Raoult</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Chloroquine and hydroxychloroquine as available weapons to fight COVID-19</article-title>
        <source>Int J Antimicrob Agents</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105932</pub-id>
        <?supplied-pmid 32205204?>
        <pub-id pub-id-type="pmid">32205204</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>McCarty</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>DiNicolantonio</surname>
            <given-names>JJ</given-names>
          </name>
        </person-group>
        <article-title>Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus</article-title>
        <source>Prog Cardiovasc Dis</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.1016/j.pcad.2020.02.007</pub-id>
        <?supplied-pmid 32061635?>
        <pub-id pub-id-type="pmid">32061635</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hensley</surname>
            <given-names>LE</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Interferon-β 1a and SARS coronavirus replication</article-title>
        <source>Emerg Infect Dis</source>
        <year>2004</year>
        <volume>10</volume>
        <fpage>317</fpage>
        <lpage>319</lpage>
        <pub-id pub-id-type="doi">10.3201/eid1002.030482</pub-id>
        <pub-id pub-id-type="pmid">15030704</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sahin</surname>
            <given-names>AR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>2019 novel coronavirus (COVID-19) outbreak: a review of the current literature</article-title>
        <source>Eur J Med Oncol</source>
        <year>2020</year>
        <volume>4</volume>
        <fpage>1</fpage>
        <lpage>7</lpage>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title>
        <source>Cell Res</source>
        <year>2020</year>
        <volume>30</volume>
        <fpage>269</fpage>
        <lpage>271</lpage>
        <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id>
        <pub-id pub-id-type="pmid">32020029</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gordon</surname>
            <given-names>DE</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title>
        <source>Nature</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id>
        <?supplied-pmid 33116285?>
        <pub-id pub-id-type="pmid">33116285</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wishart</surname>
            <given-names>DS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>
        <source>Nucl Acids Res</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D1074</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>
        <pub-id pub-id-type="pmid">29126136</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics</article-title>
        <source>Nucl Acids Res</source>
        <year>2020</year>
        <volume>48</volume>
        <fpage>D1031</fpage>
        <lpage>D1041</lpage>
        <?supplied-pmid 31691823?>
        <pub-id pub-id-type="pmid">31691823</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Alaimo</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pulvirenti</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <person-group person-group-type="editor">
          <name>
            <surname>Vanhaelen</surname>
            <given-names>Q</given-names>
          </name>
        </person-group>
        <article-title>Network-based drug repositioning: approaches, resources, and research directions</article-title>
        <source>Computational methods for drug repurposing</source>
        <year>2019</year>
        <publisher-loc>New York</publisher-loc>
        <publisher-name>Springer</publisher-name>
        <fpage>97</fpage>
        <lpage>113</lpage>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lotfi Shahreza</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ghadiri</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Mousavi</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Varshosaz</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>JR</given-names>
          </name>
        </person-group>
        <article-title>A review of network-based approaches to drug repositioning</article-title>
        <source>Brief. Bioinform</source>
        <year>2017</year>
        <volume>19</volume>
        <fpage>878</fpage>
        <lpage>892</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbx017</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A survey of current trends in computational drug repositioning</article-title>
        <source>Brief Bioinform</source>
        <year>2016</year>
        <volume>17</volume>
        <fpage>2</fpage>
        <lpage>12</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbv020</pub-id>
        <pub-id pub-id-type="pmid">25832646</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xue</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Review of drug repositioning approaches and resources</article-title>
        <source>Int J Biol Sci</source>
        <year>2018</year>
        <volume>14</volume>
        <fpage>1232</fpage>
        <lpage>1244</lpage>
        <pub-id pub-id-type="doi">10.7150/ijbs.24612</pub-id>
        <pub-id pub-id-type="pmid">30123072</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm</article-title>
        <source>Bioinformatics</source>
        <year>2016</year>
        <volume>32</volume>
        <fpage>2664</fpage>
        <lpage>2671</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btw228</pub-id>
        <pub-id pub-id-type="pmid">27153662</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Prediction of drug-target interactions and drug repositioning via network-based inference</article-title>
        <source>PLOS Comput Biol</source>
        <year>2012</year>
        <volume>8</volume>
        <fpage>e1002503</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1002503</pub-id>
        <pub-id pub-id-type="pmid">22589709</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Drug target predictions based on heterogeneous graph inference</article-title>
        <source>Pac. Symp. Biocomput. Pac. Symp. Biocomput.</source>
        <year>2013</year>
        <volume>2013</volume>
        <fpage>53</fpage>
        <lpage>64</lpage>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Martínez</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Navarro</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Cano</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Fajardo</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Blanco</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>DrugNet: network-based drug-disease prioritization by integrating heterogeneous data</article-title>
        <source>Artif Intell Med</source>
        <year>2015</year>
        <volume>63</volume>
        <fpage>41</fpage>
        <lpage>49</lpage>
        <pub-id pub-id-type="doi">10.1016/j.artmed.2014.11.003</pub-id>
        <pub-id pub-id-type="pmid">25704113</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
